Wall Street Zen upgraded shares of Upstream Bio (NASDAQ:UPB - Free Report) from a sell rating to a hold rating in a research report sent to investors on Friday morning.
Upstream Bio Trading Up 0.2%
NASDAQ UPB traded up $0.02 during trading on Friday, hitting $11.29. The stock had a trading volume of 272,840 shares, compared to its average volume of 332,640. Upstream Bio has a 12 month low of $5.14 and a 12 month high of $29.46. The company's 50-day moving average price is $8.69 and its two-hundred day moving average price is $11.25.
Upstream Bio (NASDAQ:UPB - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.02). The company had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.71 million. As a group, analysts anticipate that Upstream Bio will post -4.3 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Upstream Bio
A number of hedge funds have recently made changes to their positions in UPB. FMR LLC bought a new stake in Upstream Bio in the fourth quarter worth approximately $117,977,000. Orbimed Advisors LLC bought a new stake in shares of Upstream Bio in the 4th quarter worth approximately $93,603,000. Decheng Capital LLC bought a new position in shares of Upstream Bio during the 4th quarter worth $54,010,000. TCG Crossover Management LLC bought a new position in shares of Upstream Bio during the 4th quarter worth $44,856,000. Finally, Enavate Sciences GP LLC bought a new position in shares of Upstream Bio during the 4th quarter worth $40,438,000.
About Upstream Bio
(
Get Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Featured Articles
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
